Phase 4
N=839
Pharmacogenomic Evaluation of Antihypertensive Responses 2
Hypertension
Bottom Line
View on ClinicalTrials.gov: NCT01203852 ↗Enrolled (actual)
839
Serious AEs
0.4%
Results posted
May 2015
Primary outcome: Primary: Change in Blood Pressure From Baseline to Treatment — -7.56; -7.97; -7.68; -11.70 mmHg — p=<0.0001
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Metoprolol (Drug); Chlorthalidone (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Florida
- Primary completion
- Apr 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Blood Pressure From Baseline to Treatment |
-7.56; -7.97; -7.68; -11.70; -7.45; -13.65 | <0.0001 sig |
| SECONDARY Adverse Metabolic Effects |
1.02; 5.12 | <0.0001 sig |
Summary
There are many medications available for the treatment of high blood pressure (hypertension), but finding the right one for a specific patient can be challenging. In fact, it is estimated that less than 50% of people with hypertension have their blood pressure under control. The hypothesis is that genetic differences between individuals influence their response to antihypertensive medications. This study is aimed at determining the genetic factors that may influence a person's response to either a beta-blocker or a thiazide diuretic. The hope is that through this research, the investigators may someday be able to use an individual's genetic information to guide the selection of their blood pressure medicine, leading to better control of blood pressure, and less need for the current trial and error process.
Eligibility Criteria
Inclusion Criteria
- An average seated home diastolic blood pressure (DBP) > 85 mmHg and 5 minutes) clinic DBP between 90 mmHg and 110 mmHg and SBP 1.5 in men or 1.4 in women)
- Primary renal disease
- Pregnancy or lactation
- Liver enzymes > 2.5 upper limits of normal
- Current treatment with NSAIDS, cyclooxygenase-2 (COX2) inhibitors, oral contraceptives or estrogen.
Data sourced from ClinicalTrials.gov (NCT01203852). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.